Kidney Week, the American Society of Nephrology’s (ASN) five-day annual conference, just wrapped up its 2025 event in Houston, Texas. Kidney Week is the world’s premier nephrology meeting where professionals gather to network, learn the latest scientific and medical advances, and attend educational discussions with international experts. 

Today, we’ve curated a selection of posters on glomerular diseases and related topics that were presented at the 2025 ASN annual meeting, along with their summarized descriptions and conclusions. Some descriptions and conclusions were edited for brevity and clarity. The following posters are available online in the posters archive for the 2025 ASN annual meeting. Registered members have access to additional features, including direct linking, but everyone can freely view and search for individual posters at their leisure through November 9, 2026.

Thymosin-β4-Mediated Regulation of Macrophage Accumulation and Function in Glomerular Diseases

  • Description: Researchers investigated the role of macrophage-produced Tβ4 in disease progression and macrophage function.
  • Conclusion: Researchers found that Tβ4 expression by both bone marrow-derived and kidney-resident cells has a protective role in glomerular disease. The researchers postulate that Tβ4 modulates macrophage function by regulating pro-inflammatory and pro-fibrotic mediators thus modulating renal inflammation and disease progression.

Mesoscale Nanoparticle-Targeted Therapies to Treat Glomerular Diseases

  • Description: This study aimed to develop small interfering RNA and amiloride-loaded mesoscale nanoparticles to treat glomerular injury.
  • Conclusion: The researchers found that kidney-targeting polymeric mesoscale nanoparticles are a potential therapeutic cargo carrier for glomerular kidney diseases and that therapeutic cargo-loaded mesoscale nanoparticles can improve kidney function and reduce the long-term effects of renal fibrosis.

Dysmorphic vs. Isomorphic Hematuria in the Diagnostic Approach to Glomerular Diseases

  • Description: The study evaluated patients diagnosed with glomerulonephritis by assessing the prevalence of dysmorphic and isomorphic microhematuria, as well as factors associated with the presence of dysmorphic hematuria.
  • Conclusion: Dysmorphism was found in under half of the cases, with a sensitivity of 77.2% and a specificity of 100%. The presence of nephrotic proteinuria and better renal function were associated with the presence of dysmorphic hematuria.

Histopathologic Correlates and Treatment Outcomes in Elderly Patients with Glomerulonephritis: A Competing Risk Analysis

  • Description: This study evaluated possible links between treatment decisions, histopathologic findings, and clinical outcomes in older adults with glomerulonephritis.
  • Conclusion: Researchers found that in elderly patients with glomerulonephritis, immunosuppressive treatment did not improve renal outcomes. Careful selection of candidates for immunosuppressive therapy is essential, considering both histopathologic risk factors and competing risks such as death.

Nephrotic Syndrome in the Third Trimester of Pregnancy

  • Description: This case study highlights the importance of maintaining a broad differential and the utility of renal biopsy in identifying treatable glomerular diseases during pregnancy.
  • Discussion: For pregnant patients with severe or persistent nephrotic-range proteinuria, especially when atypical features are present—such as normal liver enzymes, platelets, and only mild hypertension—clinicians should expand the differential diagnosis to include glomerular diseases. Renal biopsy can be critical in distinguishing the aforementioned conditions from pre-eclampsia and help ensure that targeted, disease-specific therapy can initiate.

Sparsentan Ameliorates Proteinuria in Children with Glomerular Diseases

  • Description: Researchers presented data from a case series of pediatric patients with glomerular diseases, examining the early safety and efficacy of sparsentan.
  • Conclusion: Researchers noted a significant reduction in proteinuria in pediatric patients with glomerular diseases, even after three to four weeks of treatment with sparsentan.

Sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2025 Guideline Central, all rights reserved.